Iovance Biotherapeutics Inc (IOVA)

[GMH*]

The expense guide was given during Q4 earnings call which was after Amtagvi approval so I would expect that those ramp-up costs would already have been incorporated. Similarly, the cash runway included Amtagvi revenue expectations so that is a risk... I do think there will be 1 more secondary offering at some point. CFO said that the revenue projections included were "conservative" during the Q&A session however.

Will be interesting to see what they say regarding foreign market filings. I really am not expecting much update. Heard from another biotech that the FDA filings can be up to 1 million pages of documents/forms and I expect CHMP requires their own forms so a lot of updates. I am thinking Q2 2025 approval for Europe as my best guess.